Trial Profile
Pharmacokinetcs of atrasentan in combination with docetaxel in male patients with hormone-refractory prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2015
Price :
$35
*
At a glance
- Drugs Atrasentan (Primary) ; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- 23 Nov 2015 New trial record